Solid Biosciences Inc.

NasdaqGS:SLDB Stock Report

Market Cap: US$472.7m

Solid Biosciences Management

Management criteria checks 2/4

Solid Biosciences' CEO ist Bo Cumbo , ernannt in Dec 2022, hat eine Amtszeit von 1.08 Jahren. Die jährliche Gesamtvergütung beträgt $3.98M , bestehend aus 1.1% Gehalt und 98.9% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 0.086% der Aktien des Unternehmens, im Wert von $107.08K . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 2 Jahre bzw. 6.4 Jahre.

Key information

Bo Cumbo

Chief executive officer

US$4.0m

Total compensation

CEO salary percentage1.1%
CEO tenure1.3yrs
CEO ownership0.05%
Management average tenure2.3yrs
Board average tenure6.7yrs

Recent management updates

Recent updates

Solid Biosciences: DMD Treatment Advancement With Next-Generation Capsid

Jan 17

Solid Biosciences to acquire gene therapy company AavantiBio

Sep 30

Analysts Have Lowered Expectations For Solid Biosciences Inc. (NASDAQ:SLDB) After Its Latest Results

Apr 30
Analysts Have Lowered Expectations For Solid Biosciences Inc. (NASDAQ:SLDB) After Its Latest Results

Some Analysts Just Cut Their Solid Biosciences Inc. (NASDAQ:SLDB) Estimates

Apr 28
Some Analysts Just Cut Their Solid Biosciences Inc. (NASDAQ:SLDB) Estimates

We're Keeping An Eye On Solid Biosciences' (NASDAQ:SLDB) Cash Burn Rate

Mar 17
We're Keeping An Eye On Solid Biosciences' (NASDAQ:SLDB) Cash Burn Rate

Solid Biosciences (NASDAQ:SLDB) Is In A Good Position To Deliver On Growth Plans

Oct 28
Solid Biosciences (NASDAQ:SLDB) Is In A Good Position To Deliver On Growth Plans

We're Not Very Worried About Solid Biosciences' (NASDAQ:SLDB) Cash Burn Rate

Jul 13
We're Not Very Worried About Solid Biosciences' (NASDAQ:SLDB) Cash Burn Rate

We're Hopeful That Solid Biosciences (NASDAQ:SLDB) Will Use Its Cash Wisely

Mar 17
We're Hopeful That Solid Biosciences (NASDAQ:SLDB) Will Use Its Cash Wisely

Soild Bio sinks 13% after Sarepta data misses goal

Jan 08

Solid Biosciences launches $90M private placement

Dec 11

Solid Biosciences: Does Not Look Like A Solid Investment Given Its Unsatisfactory Trial Data

Nov 10

CEO Compensation Analysis

How has Bo Cumbo's remuneration changed compared to Solid Biosciences's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2023n/an/a

-US$96m

Sep 30 2023n/an/a

-US$91m

Jun 30 2023n/an/a

-US$90m

Mar 31 2023n/an/a

-US$91m

Dec 31 2022US$4mUS$46k

-US$86m

Vergütung im Vergleich zum Markt: BoDie Gesamtvergütung ($USD3.98M) liegt über dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt US ($USD738.70K).

Entschädigung vs. Einkommen: Unzureichende Daten, um die Vergütung von Bo mit der Unternehmensleistung zu vergleichen.


CEO

Bo Cumbo (52 yo)

1.3yrs

Tenure

US$3,975,453

Compensation

Mr. Alexander G. Cumbo, also known as Bo, serves as President, Chief Executive Officer and Director at Solid Biosciences Inc. since December 02, 2022. He serves as its Director of Verve Therapeutics, Inc....


Leadership Team

NamePositionTenureCompensationOwnership
Ian Smith
Executive Chair4yrsUS$637.80k0.26%
$ 1.3m
Alexander Cumbo
President1.3yrsUS$3.98m0.046%
$ 218.3k
Ilan Ganot
Co-founder11.3yrsUS$2.21m0.32%
$ 1.5m
David Howton
COO & Secretary1.3yrsUS$2.38m0.020%
$ 96.2k
Gilad Hayeem
Co-Founder11.3yrsno datano data
Annie Ganot
Co-Founder & Head of Patient Advocacyno datano datano data
Andrey Zarur
Co-Founder11.3yrsUS$125.76kno data
Kevin Tan
CFO & Treasurer1.3yrsno data0.025%
$ 116.5k
Stephen J. Palma
Treasurer & Principal Accounting Officer3.3yrsno datano data
Paul Herzich
Chief Technology Officer1.3yrsno data0.016%
$ 75.4k
Jennifer Marlowe
Chief Scientific Officerless than a yearno data0.019%
$ 87.6k
Allison Bogosian
Senior Vice President of Human Resources2.3yrsno datano data

2.3yrs

Average Tenure

51.5yo

Average Age

Erfahrenes Management: SLDBDas Führungsteam des Unternehmens gilt als erfahren (2 Jahre durchschnittliche Betriebszugehörigkeit).


Board Members

NamePositionTenureCompensationOwnership
Ian Smith
Executive Chair4yrsUS$637.80k0.26%
$ 1.3m
Alexander Cumbo
President1.3yrsUS$3.98m0.046%
$ 218.3k
Ilan Ganot
Co-founder11.3yrsUS$2.21m0.32%
$ 1.5m
Jeffrey Bluestone
Member of Scientific Advisory Boardno datano datano data
Rajeev Shah
Independent Director7.1yrsUS$130.95kno data
Adam Koppel
Director1.3yrsUS$102.14kno data
Jeffrey Chamberlain
Chairman of Scientific Advisory Board6.3yrsno datano data
Adam Stone
Lead Independent Director8.4yrsUS$137.53k0%
$ 0
Lynne Sullivan
Independent Director8.4yrsUS$142.11k0%
$ 0
Carrie Miceli
Member of Scientific Advisory Boardno datano datano data
Ronald Cohn
Member of Scientific Advisory Boardno datano datano data
Dongsheng Duan
Member of Scientific Advisory Boardno datano datano data

6.7yrs

Average Tenure

52.5yo

Average Age

Erfahrener Vorstand: SLDBDie Vorstandsmitglieder gelten als erfahren (6.3 Jahre durchschnittliche Amtszeit).


Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.